Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D03EFD
|
|||
| Former ID |
DIB011163
|
|||
| Drug Name |
KT-95
|
|||
| Synonyms |
KT-90
Click to Show/Hide
|
|||
| Indication | Inflammatory bowel disease [ICD-11: DD72; ICD-10: K50-K52] | Terminated | [1] | |
| Company |
Toho Chemical Industry Co
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C24H25NO5S
|
|||
| Canonical SMILES |
CC(=O)OC1=C2C3=C(C=C1)C(=O)C4C5C3(CCN4CC6CC6)C(O2)C(C=C5)SC(=O)C
|
|||
| InChI |
1S/C24H25NO5S/c1-12(26)29-17-7-5-15-19-22(17)30-23-18(31-13(2)27)8-6-16-20(21(15)28)25(11-14-3-4-14)10-9-24(16,19)23/h5-8,14,16,18,20,23H,3-4,9-11H2,1-2H3/t16-,18+,20-,23-,24-/m0/s1
|
|||
| InChIKey |
JALSXEHOWOEHCB-SDAQKBEVSA-N
|
|||
| PubChem Compound ID | ||||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Opioid receptor kappa (OPRK1) | Target Info | Modulator | [2] |
| KEGG Pathway | Neuroactive ligand-receptor interaction | |||
| Panther Pathway | Heterotrimeric G-protein signaling pathway-Gi alpha and Gs alpha mediated pathway | |||
| Heterotrimeric G-protein signaling pathway-Gq alpha and Go alpha mediated pathway | ||||
| Opioid prodynorphin pathway | ||||
| Reactome | Peptide ligand-binding receptors | |||
| G alpha (i) signalling events | ||||
| WikiPathways | GPCRs, Class A Rhodopsin-like | |||
| Peptide GPCRs | ||||
| GPCR ligand binding | ||||
| GPCR downstream signaling | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800007966) | |||
| REF 2 | URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 318). | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.